AUA ABSTRACT

Effects of Testosterone Administration on Prostate Tissues
In Men with ADAM Syndrome

Authors: Leonard Marks, Malu Macairan (UCLA & Urological Sciences Research Foundation), Norman Mazer (Boston University), David Hess (Oregon Health Sciences University), Peter Nelson (Fred Hutchinson Cancer Center), David Bostwick and Junqi Qian (Bostwick Laboratories), Frederick Dorey (USC), Jonathan Epstein, Robert Veltri, Alan Partin (Brady Urological Institute of Johns Hopkins University)

Introduction and Objective
Prostate safety is a major concern when aging men receive supplemental testosterone (T). However, effects of T on prostate tissues are largely unknown, and T treatment of aging men is increasing. Thus, we performed a randomized clinical trial (RCT) studying effects of T on prostate tissues in men with ADAM syndrome (androgen decline of aging male).
Methods

48 men, ages 50-75 y.o., with ADAM (+ Morley score and morning T < 300 ng/dl at screen) were enrolled. At baseline, all men underwent 14-core TRUS-guided biopsy of prostate peripheral zone (PZ); 4 had cancer (CaP) and were excluded. The remaining 44 were randomized to a 6-month trial of T enanthate 150 mg IM q2weeks or PBO, with repeat biopsy at end of study. Two biopsy cores were snap-frozen for tissue hormone levels; 12 cores were used for detailed histology and biomarker studies for cell proliferation (Ki-67, MIB-1), stroma-epithelial ratio (SER), androgen receptor (AR), angiogenesis (CD34), and gene-expression profiling using a microarray of prostate cDNAs. Prostate volume (PV) was measured by MRI. The study was powered to detect a 25% increase in dihydrotestosterone (DHT) in prostate tissue (Urology 57:999, 2001).

Results

41 men completed both baseline & 6-month biopsies: 21 on T, 20 on PBO. The groups were comparable at baseline for age (65.4 ± 9.0); serum T (299 ± 98 ng/dl) and DHT (29.4 ± 10.4); PSA (median 1.3 ng/ml); PV (46.9 ± 26.0 cc); and median prostate levels of T (1.1 ng/g) and DHT (7.1 ng/g).
T treatment raised serum T levels (7 days after last injection) to 693 ± 250 ng/dl and DHT to 51.7 ± 24.4 ng/dl (both p<0.01); hematocrit increased by 4.7 ± 2.9 % (p<0.05). However, prostate levels of T and DHT did not change from baseline in either group. PSA, PV, tissue biomarkers, and histologic indices for % atrophy and inflammation were also unchanged. Gene expression profiles of prostate epithelial cells before and after T replacement showed no treatment effect. At 6-month biopsy, CaP was found in 4 men on PBO and 2 on T.

**Conclusions**

Surprisingly, no prostate tissue changes attributable to testosterone (T) supplementation were found in this RCT. Despite marked increases in serum levels, prostate levels of T & DHT were unchanged after 6 months of treatment. Furthermore, gene expression was not altered, cell proliferation was not accelerated, and histologic cancers were not increased. While a large RCT is needed to assess long-term risks, in the short term (6 months) T supplementation appears to exert no adverse effects in prostate tissues of men with ADAM syndrome.

Source of Funding: Watson Laboratories and Solvay Pharmaceuticals
Session Type: Podium

Session Title: Sexual Function/Dysfunction/Andrology: Medical & Non-Surgical Therapy (I)

Session Start: 5/22/2006 10:00:00 AM

Session End: 5/22/2006 12:00:00 PM

Location: